Fujifilm Holdings Corp has said it has signed a manufacturing contract agreement with US-based firm VLP Therapeutics for a Covid-19 vaccine formulation.

Japan’s Fujifilm will use its manufacturing facilities and infrastructure to handle development of the vaccine for clinical trials, the two companies said in a statement.

VLP’s RNA-based vaccine candidate was selected for funding by the Japan Agency for Medical Research and Development.